Adam on for Jess's questions to Legend Biotech Corp (LEGN) leadership • Q2 2025
Question
An analyst on behalf of Jessica Fye asked for commentary on a recent 'Blood' paper regarding real-world neurotoxicity rates with CARVYKTI and for an update on the therapy's penetration into the second-to-fourth line setting.
Answer
Interim CFO Jessie Yeung highlighted the paper's finding of no Parkinsonism events with Talvey bridging therapy. President of CARVYKTI Alan Bash reiterated that the second-to-fourth line setting is the main growth driver, representing an 80,000-patient global opportunity. CEO Ying Huang emphasized the paper's importance, noting the favorable safety results in a heavily pretreated population.